QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

$82.00
-6.71 (-7.56%)
(As of 02/28/2024 ET)
Today's Range
$81.38
$88.43
50-Day Range
$73.89
$89.93
52-Week Range
$36.42
$99.63
Volume
1.37 million shs
Average Volume
596,779 shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$98.75

TransMedics Group MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
26.5% Upside
$103.75 Price Target
Short Interest
Healthy
15.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of TransMedics Group in the last 14 days
Based on 34 Articles This Week
Insider Trading
Selling Shares
$5.24 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.80) to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

901st out of 945 stocks

Electromedical Equipment Industry

19th out of 20 stocks


TMDX stock logo

About TransMedics Group Stock (NASDAQ:TMDX)

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TMDX Stock Price History

TMDX Stock News Headlines

Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TransMedics Group Becomes Oversold (TMDX)
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $105.00
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Transmedics Group Inc Earnings Call
TransMedics Shares Rise 19% as Company Reports 4Q Gain
TransMedics Group Q4 2023 Earnings Preview
TMDX Jul 2024 115.000 call
TransMedics Group (TMDX) to Release Quarterly Earnings on Monday
TMDX Dec 2024 25.000 call
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
2/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
212
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$103.75
High Stock Price Target
$110.00
Low Stock Price Target
$95.00
Potential Upside/Downside
+20.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-36,230,000.00
Pretax Margin
-19.41%

Debt

Sales & Book Value

Annual Sales
$241.62 million
Book Value
$5.87 per share

Miscellaneous

Free Float
30,461,000
Market Cap
$2.68 billion
Optionable
Optionable
Beta
2.05
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














TMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price target for 2024?

6 Wall Street analysts have issued 12 month price objectives for TransMedics Group's shares. Their TMDX share price targets range from $95.00 to $110.00. On average, they predict the company's share price to reach $103.75 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2024?

TransMedics Group's stock was trading at $78.93 on January 1st, 2024. Since then, TMDX stock has increased by 3.9% and is now trading at $82.00.
View the best growth stocks for 2024 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, February, 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 2.28%. The business's quarterly revenue was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.21) earnings per share.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.71%), Eventide Asset Management LLC (3.05%), Sandhill Capital Partners LLC (2.34%), First Light Asset Management LLC (2.31%), Allspring Global Investments Holdings LLC (2.17%) and Bellevue Group AG (1.59%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMDX) was last updated on 2/28/2024 by MarketBeat.com Staff